Dan’s Biz Bookshelf: ‘Dream First, Details Later
Happy’s Tech Talk #40: Factors in PTH Reliability—Hole Voids
Facing the Future: Time for Real Talk, Early and Often, Between Design and Fabrication
High-Tech Stick Can Predict Your Risk of Heart Problems
August 28, 2019 | RMIT UniversityEstimated reading time: 2 minutes
A hand-held device to predict heart failure based on saliva could help millions of potential victims take preventative steps to avoid their fate.
Nano-sensors on the tip of the diagnostic stick measure heart disease biomarkers to accurately predict the risk of heart disease, failure or heart attack, then warn users via a simple app.
RMIT University and the Innovative Manufacturing Cooperative Research Centre (IMCRC) are now researching and developing the device for pilot manufacture, with expectations it will hit market by 2021, in a collaboration led by Melbourne-based start-up, ESN Cleer.
RMIT University nanotechnology and design experts join forces with ESN Cleer and the Innovative Manufacturing CRC to bring the device to market by 2021. Photo: Adam R. Thomas
ESN Cleer CEO Leopoldt de Bruin said the team represented some of the best minds in medical device innovation, design and manufacture.
“We’re really pleased to be able to bring these strands together in addressing such a major global health challenge,” De Bruin said.
“Of the 400 million people who suffer from cardiovascular disease globally, only 16 per cent of cases are due to genetic traits. This underlines how much room there is to improve on screening and prevention, which is where this device could have such an impact.”
Cardiovascular disease currently accounts for nearly one-third of all global disease deaths each year.
Research Co-Director of RMIT University’s Functional Materials and Microsystems Research Group, Professor Sharath Sriram, said this was the first portable heart disease test with such high levels of accuracy.
The sensing technology, developed at RMIT University’s cutting-edge Micro Nano Research Facility, was validated in the lab to measure biomarker concentrations a thousand times more precisely than levels in human body fluids.
“This marks a big step forward in technology for screening,” Sriram said.
“Often, blood tests are only conducted after a heart failure episode. Such reactive testing is too late, leaving people with debilitating illness or leading to deaths.”
“Prevention is always better than cure, which is where this technology comes in, adding accurate prediction to the mix.”
Page 1 of 2
Share on:
Suggested Items
Kitron Reports Strengthening Momentum in Q2 2025
07/10/2025 | KitronKitron reported solid quarterly sales and profits, particularly driven by the Defence & Aerospace market sector.
Infineon Advances on 300-millimeter GaN Manufacturing Roadmap as Leading Integrated Device Manufacturer (IDM)
07/10/2025 | InfineonAs the demand for gallium nitride (GaN) semiconductors continues to grow, Infineon Technologies AG is poised to capitalize on this trend and solidify its position as a leading Integrated Device Manufacturer (IDM) in the GaN market.
TTCI Joins Printed Circuit Engineering Association to Strengthen Design-to-Test Collaboration and Workforce Development
07/09/2025 | The Test Connection Inc.The Test Connection Inc. (TTCI), a leading provider of electronic test and manufacturing solutions, is proud to announce its membership in the Printed Circuit Engineering Association (PCEA), further expanding the company’s efforts to support cross-functional collaboration, industry standards, and technical education in the printed circuit design and manufacturing community.
GlobalFoundries to Acquire MIPS to Accelerate AI and Compute Capabilities
07/09/2025 | GlobalFoundriesGlobalFoundries announced a definitive agreement to acquire MIPS, a leading supplier of AI and processor IP. This strategic acquisition will expand GF’s portfolio of customizable IP offerings, allowing it to further differentiate its process technologies with IP and software capabilities.
LITEON Technology Reports Consolidated June Sales of NT$13.6 Billion, Up 16% Y-o-Y
07/08/2025 | LITEON TechnologyLITEON Technology reported its June consolidated revenue of NT$13.6 billion. Thanks to the growth from power management in cloud computing, advanced server, and networking, the revenue is up 2% M-o-M, 16% Y-o-Y. The cumulative sales for January to June totaled NT$76.8 billion, up 24%, Y-o-Y.